← Back to Clinical Trials
Recruiting Phase 3 NCT07092930

NCT07092930 Effects of β-alanine and Sodium Bicarbonate Supplementation on Physical Capacity and Biochemical Markers Concentrations

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07092930
Status Recruiting
Phase Phase 3
Sponsor Poznan University of Physical Education
Condition Supplementation
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2023-10-01
Primary Completion 2025-12

Eligibility & Interventions

Sex Female only
Min Age 16 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
BA and SB supplementationBA and PL2 supplementationPL1 and SB supplementation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 100 participants in total. It began in 2023-10-01 with a primary completion date of 2025-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This randomized, double-blind, placebo-controlled, parallel-group study aims to evaluate the potential synergistic effect of beta-alanine (BA) and sodium bicarbonate (SB) supplementation, compared to their separate administration or placebo (PL), on physical performance and selected blood biochemical markers in highly trained female basketball players.

Eligibility Criteria

Inclusion Criteria: * written consent to participate, * general good health condition, * a current medical clearance to practice sports, * training experience: at least 4 years, * minimum of 4 workout sessions (in the discipline covered by the study) a week. Exclusion Criteria: * current injury, * any health-related contraindication, * declared general feeling of being unwell, * taking supplements, especially ergogenic supplements that modulate extra- and intracellular capacity 3 months prior to research (except taking protein and/or carbohydrate powders, isotonic drinks), * unwilling to follow the study protocol.

Contact & Investigator

Central Contact

Jakub Adamczewski, MSc

✉ adamczewski@awf.poznan.pl

📞 +48 66 317 56 06

Principal Investigator

Krzysztof Durkalec-Michalski, PhD

STUDY CHAIR

Department of Sports Dietetics, Poznan University of Physical Education Poznań

Frequently Asked Questions

Who can join the NCT07092930 clinical trial?

This trial is open to female participants only, aged 16 Years or older, up to 40 Years, studying Supplementation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07092930 trial and what does that mean for participants?

Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 100 participants.

Is NCT07092930 currently recruiting?

Yes, NCT07092930 is actively recruiting participants. Contact the research team at adamczewski@awf.poznan.pl for enrollment information.

Where is the NCT07092930 trial being conducted?

This trial is being conducted at Poznan, Poland.

Who is sponsoring the NCT07092930 clinical trial?

NCT07092930 is sponsored by Poznan University of Physical Education. The principal investigator is Krzysztof Durkalec-Michalski, PhD at Department of Sports Dietetics, Poznan University of Physical Education Poznań. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology